Japanese / English

Research Collaboration

Our advantage

Drugs that only Nippon Shinyaku can make
A future that only Nippon Shinyaku can create

Nippon Shinyaku has gained extensive experience in our focused therapeutic areas. Thanks to our research and development achievements and sales performance in the urology, hematology and intractable/orphan disease fields, we have built up trust with the stakeholders. In 2016, we launched our original drug Uptravi® for the treatment of pulmonary arterial hypertension (PAH). Uptravi® is an orally available selective IP prostacyclin receptor agonist and is the first such drug in the world. Uptravi® is now being used to treat PAH patients around the world.

Nippon Shinyaku aims to create effective therapeutic agents for intractable diseases that have yet to find an effective cure. Nucleic acid drug research is one of our key advantages. We have been focused on this field and its applications to next-generation drugs for more than 20 years. Now we have developed Viltepso® (NS-065/NCNP-01) for the treatment of Duchenne muscular dystrophy (DMD) through collaborative research with the National Center of Neurology and Psychiatry (NCNP). Viltepso® (NS-065/NCNP-01) has received SAKIGAKE designation from the Ministry of Health, Labour and Welfare, and in the U.S. it has been granted fast track, orphan drug, and rare pediatric disease designations by the FDA. Viltepso® (NS-065/NCNP-01), as Japan’s first-ever antisense nucleic acid drug, was approved in Japan in 2020 and is applied for approval in the US.

Our achievements and experience are supported by the enthusiasm of our employees, who wish to provide new drugs to patients struggling with illness as soon as possible. We share the same goal with you and we will develop new drugs with sincerity.